Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II lenalidomide + rituximab maintenance in transplant-ineligible primary CNS diffuse large B-cell lymphoma
KCT0004946Phase 2Not yet recruiting
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide, rituximab in Diffuse Large B-Cell Primary Central Nervous System Lymphoma, sponsored by Samyang Biopharmaceuticals Corporation. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
lenalidomiderituximab
03
Conditions
Diffuse Large B-Cell Primary Central Nervous System Lymphoma
Beyond the preview
Go deeper on KCT0004946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004946.